An insight into the diagnosis and pathogenesis of hepatitis C virus infection

World Journal of Gastroenterology

Volumn 19, Issue 44, 2013, Pages 7896-7909

  Irshad, Mohammad ^a   Mankotia, Dhananjay Singh ^a   Irshad, Khushboo ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Diagnosis; Hepatitis C virus; Immunity; Pathogenesis; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; CD19 ANTIGEN; CD81 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYTOCHROME P450 2D6; HEPATITIS C ANTIBODY; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 12; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RETINOIC ACID INDUCIBLE PROTEIN I; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN; VIRUS RNA;

ADAPTIVE IMMUNITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; INSULIN RESISTANCE; LIVER METABOLISM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS ENTRY;

DIAGNOSIS; HEPATITIS C VIRUS; IMMUNITY; PATHOGENESIS; STEATOSIS;

ADAPTIVE IMMUNITY; BIOLOGICAL MARKERS; DNA, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LIVER; MULTIPLEX POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 84888582305     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i44.7896     Document Type: Article

References (167)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562 DOI: 10.1126/Science. 2523562]
2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364 [PMID: 2496467 DOI: 10.1126/science.2496467]
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46 [PMID: 12407575 DOI: 10.1002/hep.1840360706]
4. Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis 2003; 16: 587-592 [PMID: 14624110 DOI: 10.1097/00001432-200312000-00012]
5. Testino G, Sumberaz A, Leone S, Borro P. Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review. Minerva Med 2013; 104: 225-232 [PMID: 23514999]
6. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM. Fields virology. Philadelphia: Lippubcott Williams and Wilkins, 2001: 991-1041
7. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-583 [PMID: 7531173 DOI: 10.1002/ hep.1840210243]
8. Yamane D, McGivern DR, Masaki T, Lemon SM. Liver injury and disease pathogenesis in chronic hepatitis C. Curr Top Microbiol Immunol 2013; 369: 263-288 [PMID: 23463205 DOI:10.1007/978-3-642-27340-7_11]
9. Irshad M, Ansari MA, Singh A, Nag P, Raghvendra L, Singh S, Badhal SS. HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment. Hepatogastroenterology 2010; 57: 1529-1538 [PMID: 21443116]
10. Das BR, Kundu B, Khandapkar R, Sahni S. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002; 45: 323-328 [PMID: 12785176]
11. Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, Midha V, Sakhuja P, Malhotra V, Sarin SK. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006; 78: 452-458 [PMID: 16482560 DOI:10.1002/jmv.20561]
12. Irshad M, Acharya SK, Joshi YK. Prevalence of hepatitis C virus antibodies in the general population & amp; in selected groups of patients in Delhi. Indian J Med Res 1995; 102: 162-164 [PMID: 8543360]
13. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190: 894-899 [PMID: 1325713 DOI: 10.1016/0042-6822(92)90933-G]
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]
15. Pawlotsky JM. Treatment failure and resistance with directacting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-1751 [PMID: 21374691 DOI: 10.1002/ hep.24262]
16. Huang Y, Yang H, Borg BB, Su X, Rhodes SL, Yang K, Tong X, Tang G, Howell CD, Rosen HR, Thio CL, Thomas DL, Alter HJ, Sapp RK, Liang TJ. A functional SNP of interferongamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 2007; 104: 985-990 [PMID: 17215375 DOI:10.1073/pnas.0609954104]
17. Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, Egashira T, Hashimoto M, Mishiro S, Mochida S, Fujiwara K. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 381-388 [PMID: 15868370 DOI: 10.1007/s00535-005-1558-3]
18. Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013; 207 Suppl 1: S7-S12 [PMID: 23390305 DOI: 10.1093/infdis/jis762]
19. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626 [PMID: 15947137 DOI:10.1126/science.1114016]
20. Abstracts of the 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, France, July 1-5, 2006. J Clin Virol 2006; 36 Suppl 2: S1-218 [PMID: 16858847]
21. Ndimbie OK, Nedjar S, Kingsley L, Riddle P, Rinaldo C. Long-term serologic follow-up of hepatitis C virus-seropositive homosexual men. Clin Diagn Lab Immunol 1995; 2: 219-224 [PMID: 7697532]
22. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135-140 [PMID: 1279801 DOI:10.1126/science.1279801]
23. Yuki N, Hayashi N, Ohkawa K, Hagiwara H, Oshita M, Katayama K, Sasaki Y, Kasahara A, Fusamoto H, Kamada T. The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C. Hepatology 1995; 22: 402-406 [PMID: 7543432]
24. Kesli R. An Overview of the Laboratory Assay Systems and Reactives Used in the Diagnosis of Hepatitis C Virus (HCV) Infections. In: Abuelzein E, editor. Trends in Immunolabelled and Related Techniques. Rijeka: InTech, 2012: 340-350 [DOI: 10.5772/35183]
25. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Detection of hepatitis C virus RNA in acute non-A, non-B hepatitis as an early diagnostic tool. Biochem Biophys Res Commun 1993; 192: 800-807 [PMID: 7683464 DOI: 10.1006/ bbrc.1993.1485]
26. Kao JH, Chen PJ, Lai MY, Chen DS. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterology 1993; 105: 583-587 [PMID: 8392958]
27. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388-390 [PMID: 7905553 DOI:10.1016/S0140-6736(94)91224-6]
28. Ansari MA, Irshad M, Agarwal SK, Chosdol K. Expression of the full-length HCV core subgenome from HCV gentoype-1a and genotype-3a and evaluation of the antigenicity of translational products. Eur J Gastroenterol Hepatol 2013; 25: 806-813 [PMID: 23442416 DOI: 10.1097/MEG.0b013e32835eb9b9]
29. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500 [PMID: 2509915 DOI: 10.1056/ NEJM198911303212202]
30. Chien DY, Choo QL, Ralston R, Spaete R, Tong M, Houghton M, Kuo G. Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet 1993; 342: 933 [PMID: 7692197 DOI: 10.1016/0140-6736(93)91983-S]
31. Chemello L, Cavalletto D, Pontisso P, Bortolotti F, Donada C, Donadon V, Frezza M, Casarin P, Alberti A. Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. Hepatology 1993; 17: 179-182 [PMID: 8381380 DOI: 10.1002/hep.1840170203]
32. Irshad M, Ansari MA, I K, L R. A Novel Single Step Multiplex Real Time Pcr Assay for Simultaneous Quantification of Hepatitis Virus A, B, C & E in Serum. J Gastroenterol Hepatol 2013; Epub ahead of print [PMID: 23800094 DOI: 10.1111/ jgh.12302]
33. Yang JH, Lai JP, Douglas SD, Metzger D, Zhu XH, Ho WZ. Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods 2002; 102: 119-128 [PMID: 11879700 DOI:10.1016/S0166-0934(02)00007-1]
34. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/ hep.22759]
35. Irshad M, Dhar I. Hepatitis C virus core protein: an updateon its molecular biology, cellular functions and clinical implications. Med Princ Pract 2006; 15: 405-416 [PMID: 17047346 DOI: 10.1159/000095485]
36. Haid S, Grethe C, Dill MT, Heim M, Kaderali L, Pietschmann T. Isolate-dependent use of Claudins for cell entry by hepatitis C virus. Hepatology 2013; Epub ahead of print [PMID: 23775920 DOI: 10.1002/hep.26567]
37. Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S, Uematsu Y. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 2002; 304: 187-196 [PMID: 12504561 DOI: 10.1006/viro.2002.1631]
38. Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry. Curr Top Microbiol Immunol 2013; 369: 87-112 [PMID: 23463198 DOI: 10.1007/978-3-642-27340-7_4]
39. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997; 11: 428-442 [PMID: 9194523]
40. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999; 73: 6235-6244 [PMID: 10400713]
41. Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foung S, Amara A, Houles C, Fieschi F, Schwartz O, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R. DCSIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 2003; 278: 20358-20366 [PMID: 12609975 DOI: 10.1074/jbc.M301284200]
42. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025 [PMID: 12356718 DOI: 10.1093/emboj/cdf529]
43. Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, Acali S, Pezzanera M, Ercole BB, McKeating J, Yagnik A, Lahm A, Tramontano A, Cortese R, Nicosia A. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 2003; 77: 1856-1867 [PMID: 12525620 DOI: 10.1128/JVI.77.3.1856-1867.2003]
44. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454: 523-527 [PMID: 18548002 DOI: 10.1038/nature07106]
45. Liu HM, Gale M. Hepatitis C Virus Evasion from RIG-I-Dependent Hepatic Innate Immunity. Gastroenterol Res Pract 2010; 2010: 548390 [PMID: 21274284 DOI:10.1155/2010/548390]
46. Saito T, Gale M. Regulation of innate immunity against hepatitis C virus infection. Hepatol Res 2008; 38: 115-122 [PMID: 18021225]
47. Saito T, Gale M. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J Exp Med 2008; 205: 1523-1527 [PMID: 18591413 DOI: 10.1084/ jem.20081210]
48. Schoggins JW, Rice CM. Innate immune responses to hepatitis C virus. Curr Top Microbiol Immunol 2013; 369: 219-242 [PMID: 23463203 DOI: 10.1007/978-3-642-27340-7_9]
49. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM, Gale M. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006; 103: 6001-6006 [PMID: 16585524 DOI: 10.1073/pnas.0601523103]
50. Golden-Mason L, Rosen HR. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev 2013; 255: 68-81 [PMID: 23947348 DOI: 10.1111/ imr.12090]
51. Zinkernagel RM, Haenseler E, Leist T, Cerny A, Hengartner H, Althage A. T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay? J Exp Med 1986; 164: 1075-1092 [PMID: 3489805 DOI: 10.1084/ jem.164.4.1075]
52. Neumann-Haefelin C, Thimme R. Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol 2013; 369: 243-262 [PMID: 23463204 DOI: 10.1007/9 78-3-642-27340-7_10]
53. Malta FM, Bruno FR, Carvalho KI, Nastri AC, Kalil J, Carrilho FJ, Kallas EG, Pinho JR. HCV viremia drives an increment of CD86 expression by myeloid dendritic cells. J Med Virol 2013; 85: 1919-1924 [PMID: 23926073 DOI: 10.1002/ jmv.23692]
54. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW, Carson WE. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol 2011; 186: 3401-3409 [PMID: 21321106 DOI: 10.4049/jimmunol.1000328]
55. Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, Schuler G. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996; 26: 659-668 [PMID: 8605935 DOI: 10.1002/eji.1830260323]
56. Holder KA, Stapleton SN, Gallant ME, Russell RS, Grant MD. Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions. J Immunol 2013; 191: 3308-3318 [PMID: 23960237 DOI: 10.4049/jimmunol]
57. Zhang S, Saha B, Kodys K, Szabo G. IFN-γ production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J Hepatol 2013; 59: 442-449 [PMID: 23665181 DOI: 10.1016/j.jhep.2013.04.022]
58. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809, table of contents [PMID: 11585785 DOI:10.1128/CMR.14.4.778-809.2001]
59. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2: 585-589 [PMID: 11429541 DOI: 10.1038/89726]
60. Watarai H, Sekine E, Inoue S, Nakagawa R, Kaisho T, Taniguchi M. PDC-TREM, a plasmacytoid dendritic cell-specific receptor, is responsible for augmented production of type I interferon. Proc Natl Acad Sci USA 2008; 105: 2993-2998 [PMID: 18287072 DOI: 10.1073/pnas.0710351105]
61. Pasetto A, Aleman S, Chen M. Functional Attributes of Responding T Cells in HCV Infection: The Recent Advances in Engineering Functional Antiviral T Cells. Arch Immunol Ther Exp (Warsz) 2013; Epub ahead of print [PMID: 23955531]
62. Aberle JH, Formann E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, Grilnberger E, Laferl H, Dienes HP, Popow-Kraupp T, Ferenci P, Holzmann H. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006; 36: 24-31 [PMID: 16483838 DOI: 10.1016/j.jcv.2005.12.010]
63. Fahey S, Dempsey E, Long A. The role of chemokines in acute and chronic hepatitis C infection. Cell Mol Immunol 2013; Epub ahead of print [PMID: 23954947 DOI: 10.1038/ cmi.2013.37]
64. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52 [PMID: 11439948 DOI: 10.1056/ NEJM200107053450107]
65. Valiante NM, D'Andrea A, Crotta S, Lechner F, Klenerman P, Nuti S, Wack A, Abrignani S. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol Rev 2000; 174: 77-89 [PMID: 10807508 DOI: 10.1034/j.1600-0528.2002.017417.x]
66. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99: 15669-15674 [PMID: 12441396 DOI: 10.1073/pnas.202608199]
67. Koziel MJ. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat 1997; 4 Suppl 2: 31-41 [PMID: 9429208 DOI: 10.1111/j.1365-2893.1997.tb00178. x]
68. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 99: 1472-1477 [PMID: 9119989 DOI: 10.1172/JCI119308]
69. Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, Borrás-Cuesta F, Prieto J. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol 2003; 77: 10862-10871 [PMID: 14512536 DOI: 10.1128/JVI.77.20.1086210871.2003]
70. Szabo G, Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 2005; 210: 237-247 [PMID: 16164031 DOI:10.1016/j.imbio.2005.05.018]
71. Pöhlmann S, Zhang J, Baribaud F, Chen Z, Leslie GJ, Lin G, Granelli-Piperno A, Doms RW, Rice CM, McKeating JA. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003; 77: 4070-4080 [PMID: 12634366 DOI:10.1128/JVI.77.7.4070-4080.2003]
72. Irshad M, Khushboo I, Singh S, Singh S. Hepatitis C virus (HCV): a review of immunological aspects. Int Rev Immunol 2008; 27: 497-517 [PMID: 19065353 DOI: 10.1080/0883018080 2432178]
73. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, Saracco G, Choo QL, Houghton M. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842-848 [PMID: 1846505 DOI: 10.1016/0042-6822(91)90104-J]
74. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344 [PMID: 10764648 DOI: 10.1126/science.288.5464.339]
75. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792-7796 [PMID: 7519785 DOI: 10.1073/pnas.91.16.7792]
76. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 68: 1494-1500 [PMID: 8107212]
77. Del Porto P, Puntoriero G, Scottà C, Nicosia A, Piccolella E. High prevalence of hypervariable region 1-specific and -cross-reactive CD4(+) T cells in HCV-infected individuals responsive to IFN-alpha treatment. Virology 2000; 269: 313-324 [PMID: 10753710 DOI: 10.1006/viro.2000.0238]
78. Tsai SL, Chen YM, Chen MH, Huang CY, Sheen IS, Yeh CT, Huang JH, Kuo GC, Liaw YF. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998; 115: 954-965 [PMID: 9753499 DOI: 10.1016/S0016-5085(98)70268-9]
79. Frasca L, Scottà C, Del Porto P, Nicosia A, Pasquazzi C, Versace I, Masci AM, Racioppi L, Piccolella E. Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. Hepatology 2003; 38: 653-663 [PMID: 12939592 DOI: 10.1053/jhep.2003.50387]
80. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-662 [PMID: 14576438 DOI:10.1126/science.1088774]
81. Manzin A, Solforosi L, Petrelli E, Macarri G, Tosone G, Piazza M, Clementi M. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol 1998; 72: 6271-6276 [PMID: 9621104]
82. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999; 73: 2938-2946 [PMID: 10074143]
83. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25: 71-99 [PMID: 17067278 DOI:10.1146/annurev.immunol.25.022106.141602]
84. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004; 58: 391-424 [PMID: 15487943 DOI:10.1146/annurev.micro.58.030603.123836]
85. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-952 [PMID: 16107834 DOI: 10.1038/nature04079]
86. Kim HS, Lee JK, Yang IH, Ahn JK, Oh YI, Kim CJ, Kim YS, Lee CK. Identification of hepatitis C virus core domain inducing suppression of allostimulatory capacity of dendritic cells. Arch Pharm Res 2002; 25: 364-369 [PMID: 12135111 DOI:10.1007/BF02976640]
87. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38: 1437-1448 [PMID: 14647055]
88. + T cells during persistent hepatitis C virus infection. J Virol 2005; 79: 7852-7859 [PMID: 15919939 DOI: 10.1128/JVI.79.12.7852-7859.2005]
89. + T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol 2007; 47: 316-324 [PMID: 17475362 DOI: 10.1016/ j.jhep.2007.03.023]
90. Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 2006; 69: 129-141 [PMID: 16413618 DOI:10.1016/j.antiviral.2005.12.001]
91. + T cells during chronic hepatitis C virus infection. J Virol 2005; 79: 7860-7867 [PMID: 15919940 DOI: 10.1128/JVI.79.12.7860-7867.2005]
92. + T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol 2006; 144: 188-196 [PMID: 16634790 DOI: 10.1111/ j.1365-2249.2006.03048.x]
93. + CD45RAFoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol 2013; 173: 207-216 [PMID: 23607886 DOI:10.1111/cei.12116]
94. + T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 2006; 107: 4424-4432 [PMID: 16478885 DOI: 10.1182/blood-2005-09-3903]
95. MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J, Curry M, Mills KH. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis 2002; 185: 720-727 [PMID: 11920289 DOI: 10.1086/339340]
96. Clément S, Pascarella S, Negro F. Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress. Viruses 2009; 1: 126-143 [PMID: 21994542 DOI:10.3390/v1020126]
97. + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010; 6: e1000947 [PMID: 20548953 DOI: 10.1371/journal. ppat.1000947]
98. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81: 2545-2553 [PMID: 17182670 DOI: 10.1128/ JVI.02021-06]
99. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495 [PMID: 1383822 DOI: 10.1056/ NEJM199211193272104]
100. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, Efremov DG. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998; 91: 2433-2442 [PMID: 9516143]
101. Tan SL, Katze MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 2001; 284: 1-12 [PMID: 11352662 DOI: 10.1006/viro.2001.0885]
102. Reyes GR. The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci 2002; 9: 187-197 [PMID: 12065893 DOI: 10.1007/BF02256065]
103. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502 [PMID:15302943 DOI: 10.1099/vir.0.80204-0]
104. Fournier C, Helle F, Descamps V, Morel V, François C, Dedeurwaerder S, Wychowski C, Duverlie G, Castelain S. Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes. J Gen Virol 2013; 94: 996-1008 [PMID: 23288424 DOI: 10.1099/vir.0.049676-0]
105. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98: 9599-9604 [PMID: 11481452 DOI: 10.1073/pnas.171311298]
106. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001; 75: 1401-1407 [PMID: 11152513 DOI: 10.1128/ JVI.75.3.1401-1407.2001]
107. Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, Levy DE, Mukaida N, Gretch DR. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75: 6095-6106 [PMID: 11390611 DOI:10.1128/JVI.75.13.6095-6106.2001]
108. Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM, Gale M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148 [PMID: 12702807 DOI: 10.1126/science.1082604]
109. Pavio N, Taylor DR, Lai MM. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J Virol 2002; 76: 1265-1272 [PMID: 11773402 DOI: 10.1128/ JVI.76.3.1265-1272.2002]
110. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110 [PMID: 10390359 DOI:10.1126/science.285.5424.107]
111. Shanmugam S, Yi M. Efficiency of E2-p7 processing modulates production of infectious hepatitis C virus. J Virol 2013;87: 11255-11266 [PMID: 23946462]
112. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol 2002; 76: 11079-11090 [PMID: 12368350 DOI: 10.1128/ JVI.76.21.11079-11090.2002]
113. Tu Z, Zhang P, Li H, Niu J, Jin X, Su L. Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN. Cell Immunol 2013; 284: 98-103 [PMID: 23954883 DOI: 10.1016/ j.cellimm.2013.07.012]
114. Díaz-Valdés N, Manterola L, Belsúe V, Riezu-Boj JI, Larrea E, Echeverria I, Llópiz D, López-Sagaseta J, Lerat H, Pawlotsky JM, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 2011; 53: 23-31 [PMID: 21154952 DOI: 10.1002/hep.23980]
115. Arnaud C, Pradat P, Spaziante M, Berthillon P, Maynard M, Taliani G, Chemin I, Trépo C, Petit MA. Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes. Antivir Ther 2013; Epub ahead of print [PMID: 23948510 DOI:10.3851/IMP2671]
116. Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G, Abrignani S. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005; 102: 18544-18549 [PMID: 16339892 DOI: 10.1073/pnas.0509402102]
117. Zhao LJ, Wang L, Ren H, Cao J, Li L, Ke JS, Qi ZT. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp Cell Res 2005; 305: 23-32 [PMID: 15777784 DOI:10.1016/j.yexcr.2004.12.024]
118. Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T, Abrignani S, Pinzani M. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem 2005; 280: 11329-11339 [PMID: 15611113 DOI: 10.1074/ jbc.M410161200]
119. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, Brugnetti B, Civardi E, Salvaneschi L. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285-290 [PMID: 7843695]
120. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-235 [PMID: 10755999 DOI: 10.1128/CMR.13.2.223-235.2000]
121. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-639 [PMID: 8849147 DOI: 10.7326/0003-4819-1 25-8-199610150-00002]
122. Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann Hepatol 2010; 9 Suppl: 112-118 [PMID: 20714007]
123. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54:1003-1008 [PMID: 15951550 DOI: 10.1136/gut.2004.050302]
124. Bièche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, Bedossa P, Valla DC, Marcellin P, Vidaud M. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005; 332: 130-144 [PMID: 15661146 DOI: 10.1016/j.virol.2004.11.009]
125. Foster DA. Regulation of mTOR by phosphatidic acid? Cancer Res 2007; 67: 1-4 [PMID: 17210675 DOI: 10.1158/0008-5472. CAN-06-3016]
126. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008; 29: 381-402 [PMID: 18451260 DOI: 10.1210/er.2007-0025]
127. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848 [PMID: 14988838 DOI: 10.1053/j.gastro.2003.11.056]
128. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-1171 [PMID: 17465001 DOI: 10.1002/ hep.21634]
129. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508 [PMID: 15509521 DOI: 10.1016/S0002-9440(10)63408-6]
130. Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, Heim MH. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008; 49: 429-440 [PMID: 18486982 DOI:10.1016/j.jhep.2008.04.007]
131. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 2008; 82: 2606-2612 [PMID: 18160431 DOI: 10.1128/JVI.01672-07]
132. Fujita N, Sugimoto R, Ma N, Tanaka H, Iwasa M, Kobayashi Y, Kawanishi S, Watanabe S, Kaito M, Takei Y. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat 2008; 15: 498-507 [PMID: 18331251 DOI: 10.1111/j.1365-2893.2008.00972.x]
133. Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Serra MA, Romero FJ. Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Free Radic Biol Med 1998; 25: 993-997 [PMID: 9870551 DOI:10.1016/S0891-5849(98)00118-X]
134. Mitsuyoshi H, Itoh Y, Sumida Y, Minami M, Yasui K, Nakashima T, Okanoue T. Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. Hepatol Res 2008; 38: 348-353 [PMID: 18021228 DOI: 10.1111/j.1872-034X.2007.00280.x]
135. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069-1073 [PMID: 9322499 DOI: 10.1053/gast.1997.v113. pm9322499]
136. Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Zabrecky G, Cohen R, Ilan Y. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol 2007; 13: 5317-5323 [PMID: 17879400]
137. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375 [PMID: 11832451 DOI: 10.1053/gast.2002.30983]
138. Abdalla MY, Ahmad IM, Spitz DR, Schmidt WN, Britigan BE. Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses. J Med Virol 2005; 76: 489-497 [PMID: 15977232 DOI: 10.1002/jmv.20388]
139. Dionisio N, Garcia-Mediavilla MV, Sanchez-Campos S, Majano PL, Benedicto I, Rosado JA, Salido GM, Gonzalez Gallego J. Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J Hepatol 2009; 50: 872-882 [PMID: 19303156 DOI: 10.1016/j.jhep.2008.12.026]
140. Li Y, Boehning DF, Qian T, Popov VL, Weinman SA. Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J 2007; 21: 2474-2485 [PMID: 17392480 DOI: 10.1096/fj.06-7345com]
141. Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 2006; 80: 7199-7207 [PMID: 16809325 DOI: 10.1128/JVI.00321-06]
142. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-1097 [PMID: 17721513 DOI: 10.1038/ncb1631]
143. Joyce MA, Walters KA, Lamb SE, Yeh MM, Zhu LF, Kneteman N, Doyle JS, Katze MG, Tyrrell DL. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog 2009; 5: e1000291 [PMID: 19242562 DOI: 10.1371/journal.ppat.1000291]
144. Thorén F, Romero A, Lindh M, Dahlgren C, Hellstrand K. A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. J Leukoc Biol 2004; 76: 1180-1186 [PMID: 15371490 DOI: 10.1189/jlb.0704387]
145. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-130 [PMID: 16344578 DOI: 10.1136/gut.2005.069757]
146. Khan M, Jahan S, Khaliq S, Ijaz B, Ahmad W, Samreen B, Hassan S. Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. Arch Virol 2010; 155: 1735-1753 [PMID: 20842391 DOI:10.1007/s00705-010-0797-7]
147. Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol 2011; 26 Suppl 1: 96-101 [PMID: 21199519 DOI: 10.1111/j.1440-1746.2010.06542. x]
148. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001; 35: 307 [PMID: 11580157 DOI: 10.1016/S0168-8278(01)00087-3]
149. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406-412 [PMID: 14960525 DOI:10.1136/gut.2003.018770]
150. Roingeard P. Hepatitis C virus diversity and hepatic steatosis. J Viral Hepat 2013; 20: 77-84 [PMID: 23301542 DOI:10.1111/jvh.12035]
151. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364 [PMID: 11391523 DOI: 10.1053/ jhep.2001.24432]
152. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-881 [PMID: 12164963 DOI: 10.1046/j.1440-1746.2002.02813.x]
153. Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, Rossi C, Mangia A, Negro F. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 2005; 42: 744-751 [PMID: 15826725 DOI: 10.1016/j.jhep.2004.12.034]
154. Adinolfi LE, Restivo L, Marrone A. The predictive value of steatosis in hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2013; 7: 205-213 [PMID: 23445230 DOI: 10.1586/ egh.13.7]
155. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-1272 [PMID: 12395339 DOI: 10.1053/ jhep.2002.36370]
156. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85 [PMID: 12829989 DOI: 10.1053/jhep.2003.50267]
157. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, PeckRadosavljevic M, Osterreicher C, Mueller C, Gangl A, Ferenci P. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 2880-2885 [PMID: 12425563 DOI: 10.1111/ j.1572-0241.2002.07056.x]
158. Oem JK, Jackel-Cram C, Li YP, Zhou Y, Zhong J, Shimano H, Babiuk LA, Liu Q. Activation of sterol regulatory elementbinding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol 2008; 89: 1225-1230 [PMID: 18420801 DOI: 10.1099/vir.0.83491-0]
159. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002; 292: 198-210 [PMID: 11878923 DOI: 10.1006/ viro.2001.1225]
160. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-434 [PMID: 11322205 DOI: 10.1016/ S0168-8278(00)00036-2]
161. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-194 [PMID: 11818366 DOI: 10.1096/fj.01-0396com]
162. Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem 2009; 284: 9237-9246 [PMID: 19204002 DOI:10.1074/jbc.M808773200]
163. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46: 999-1008 [PMID: 17188392 DOI: 10.1016/ j.jhep.2006.10.019]
164. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002; 35: 937-946 [PMID: 11915042 DOI: 10.1053/ jhep.2002.32470]
165. Cheng Y, Dharancy S, Malapel M, Desreumaux P. Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. World J Gastroenterol 2005; 11: 7591-7596 [PMID: 16437683]
166. de Gottardi A, Pazienza V, Pugnale P, Bruttin F, RubbiaBrandt L, Juge-Aubry CE, Meier CA, Hadengue A, Negro F. Peroxisome proliferator-activated receptor-alpha and-gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006; 23: 107-114 [PMID: 16393287 DOI: 10.1111/ j.1365-2036.2006.02729.x]
167. Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, Gambiez L, Mathurin P, Paris JC, Schoonjans K, Calmus Y, Pol S, Auwerx J, Desreumaux P. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334-342 [PMID: 15685545 DOI: 10.1053/j.gastro.2004.11.016]